Skip to main content

entecavir (Baraclude®)

 

Following a limited submission

AWMSG advice
Status: Recommended

Entecavir (Baraclude®) is recommended as an option for use within NHS Wales for the treatment of chronic hepatitis B virus (HBV) infection in:

  • adults with decompensated liver disease;
  • nucleoside naive paediatric patients from 2 to < 18 years of age with compensated liver disease who have evidence of active viral replication and persistently elevated serum alanine aminotransferase (ALT) levels, or histological evidence of moderate to severe inflammation and/or fibrosis.
 Final Recommendation: entecavir (Baraclude) 2546 (PDF, 342Kb)
 Appraisal Report: entecavir (Baraclude) 2546 (PDF, 360Kb)

Medicine details
Medicine name entecavir (Baraclude®)
Formulation 0.5 mg film-coated tablet, 1 mg film-coated tablet, 0.05 mg/ml oral solution
Reference number 2546
Indication

Treatment of chronic hepatitis B virus infection in:

  • adults with decompensated liver disease;
  • nucleoside naive paediatric patients from 2 to < 18 years of age with compensated liver disease who have evidence of active viral replication and persistently elevated serum alanine aminotransferase (ALT) levels, or histological evidence of moderate to severe inflammation and/or fibrosis
Company Bristol-Myers Squibb Pharmaceuticals Ltd
BNF chapter Infections
Submission type Limited
Status Recommended
Advice number 0715
NMG meeting date 25/02/2015
AWMSG meeting date 25/03/2015
Ratification by Welsh Government 15/05/2015
Date of issue 20/05/2015
Date of last review 27/03/2018
Further information

This advice incorporates and replaces the AWMSG recommendation for entecavir (Baraclude® ) for the treatment of chronic hepatitis B virus infection in adults with decompensated liver disease (advice number 0212, originally published February 2012).
Follow AWTTC: